New combo therapy targets hard-to-treat lung cancer in early trial

NCT ID NCT06097962

Recruiting now Disease control Sponsor: Base Therapeutics (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times

Summary

This early-phase study tests a new treatment called NK510 (a type of immune cell therapy) combined with PD-1 inhibitors for people with advanced non-small cell lung cancer that has come back or not responded to prior treatments. The trial includes two ways to give the therapy: through a vein or directly into the chest for those with fluid buildup around the lungs. The main goals are to check safety and see if tumors shrink. Only 12 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Jinling hospital, affiliated to Medical school Nanjing University
RECRUITING

Nanjing, Jiangsu, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NSCLC